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Abstract  
Toxoplasma gondiiis an opportunistic parasitic protozoan infection. Toxoplasmosis is the most common food-
borne infection throughout the world. In pregnancy, fetal complications range from abortion, physically-
disabled children to fetal demise. This review examined risk factors diagnosis and treatment of Toxoplasma 
gondii during pregnancy pregnant.Pregnant women contract the infection through contaminated food, 
unpasteurized milk and proximity with infected animals most commonly cats. Recent evident have 
demonstrated the benefit of screening and treatment for toxoplasmosis duringperiod of pregnancyby decreasing 
vertical transmission of the Toxoplasma gondiiparasite to the growing fetus. There are several ways for pregnant 
women to protect themselves from contracting the disease during pregnancy. In this review, we discussed 
diagnosis, prevention, and management of toxoplasmosis during pregnancy. 
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1. Introduction  
Toxoplasma gondiiis intracellular protozoan with asingle-cell that infects all warm-blooded animals including 
human. This parasite causes toxoplasmosis infections, which is considered as most common human zoonotic  
and parasitic infections. It's estimated worldwide distribution ofseropositive for T. gondii, amongpopulation was 
about one-third [1]. However, seropositivity estimates vary among different countries, and in the same 
geographical areas within between different ethnic groups. The differences in seropositivity rates are greatly 
influenced by lack of standardized serological tests for used to diagnose T. gondii. Humans are infected via 
horizontal transmission by ingestion of the T. gondiiOocystsfound inundercooked or raw meat contaminated 
with feces ofcats, or from soil, or contaminated water [2]. Other rare methods of infection include vertical 
transmission from the infected mother to his fetus also duringorgantransplantation from infected donors [3]. 
Seropositivity among pregnant women in Arab and African countries is high compared to other part of the world  
[4]. 
Maternal infection with toxoplasmosis is usually subclinical, but it can complicate other maternal infection such 
as uterine gas gangrene leading to severe myonecrosis  [5].  Congenital infection T. gondii can lead to long-term 
consequences that eventually lead to fetal death. The prevalence of congenital infection with T. gondii ranges 
from 1 / 1000 live births to 1 / 10,000 live births [6].  
The risk of vertical transmission was increased among gestational age, 60% to 81% of infection occurs in the 
third trimester compared with 6% in the first trimester as previously shown [17]. The symptom and severity of 
the disease was decreased with gestational age, with first-trimester infection resulting in worst prognosis. In 
untreated cases, the overall risk of contracting congenital disease following acute infection in pregnancy ranges 
from 20% to 50% [8].90% ofA new baby born with congenital infection are asymptomatic at birth [9]. In 
immunocompetent, the disease is often asymptomatic; however, flu-like symptoms may be experienced 
including fever headache, muscular pain. The most significant clinical finding is generalized lymphadenopathy 
due to be reactive hyperplasia of lymph nodes  [10].Usually infected mothers are asymptomatic, numerous fetal 
adverse outcomes have been reported including spontaneous miscarriage, prematurity, and fetal death. In 
congenital toxoplasmosis, a wide range of fetal manifestations has been documented. In untreated symptomatic 
patients, fetal Mortality is approximates 12 %. The majority of survivals developed intellectual impairment 
(93%), seizures (81 %), motor symptoms (70 %), and severe ocular impairment (60 %). Other manifestation 
included hydrocephalus or microcephaly in 33% and progressive hearing loss in 15 % of cases [11]. However, 
severe fetal morbidities are significantly more common in offspring whose mother's infection was infected early 
in gestation [12]. 
2. Methods 
A systematic electronic data search was conducted to identify relevant published data on toxoplasmosis and 
pregnancy. The searching tools used were academic digital library of Qassim University which encompasses 
much global database for both books and electronic journals including PubMed, Medline, Elsevier, Ovid e-
Journal, Oxford Journals, EBSCO, ProQuest Central, Science Direct, Wiley-Blackwell e-Journals, Springer 
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Online Journals and, Oxford Scholarship Online, and. Besides, search engines Google (http://www.google.com) 
and Google Scholar (http://www.scholar.google.com/) were used. The following search terms were used: 
Toxoplasma gondii, pregnancy, risk factors. There was no search restriction.  
3. Diagnostic methods  
Detection of anti-toxoplasma-specific antibodies is widely used for thelaboratory  
diagnosisoftoxoplasmosisinfection[13]. In pregnancy, it is essential to perform additional tests that must include 
PCR, Ig A, IgG avidity test, and IgE, on individuals with both positive IgG and IgM [14]. Also, it is important 
to determine Toxoplasma-specific IgM antibodies as this estimate the time of infection. The problem with 
Toxoplasma-specific IgM is its non-specificity; it may persist as long as 18 months after initial infection in 
addition to its interpretation.  If the IgG is negative and the IgM is positive, the test should be repeated in 2 
weeks' time. In positive cases the IgG antibodies will be positive, the same result is obtained the result should be 
considered false positive, and the patient is not infected. A third situation, when the serologic testing is positive 
for both IgG and IgM, the individual either has an acute infection or its  false-positive result  [15]. If an acute 
infection is suspected, it is recommended to repeat the test within 2 to 3 weeks from the initial results  [16]. A 4-
fold increase in IgG titers indicates a recent infection [17]. 
Previously, individuals were classified into three categories according to seropositivity as follows: 1/ immune 
subjects with past infection with (IgG+/IgM-);  2/ those who were susceptible to primary infection poses neither 
antibodies(IgG-/IgM-), and 3/ those with acute toxoplasmosis and poses both antibodies (IgG+/IgM+). 
Furthermore, there are three major genotypes of T. gondii (type I, II and III) that are responsible for 95% of the 
isolates and remaining 5% constitutes atypical genotypes that are harmless [18]. Recently, a study showed that 
congenital T. gondiiinfection can occur in immunogenic mothers (IgG+/IgM-) by atypical genotype which was 
previously described as harmless genotype ( [19]. Furthermore, severe congenital toxoplasmosis was reported in 
non-immune mothers in the third trimester where the disease is thought to results in less severe morbidity  [20]. 
Changing the pattern of the disease endorses a new understanding of natures and treatment. The definitive 
diagnosis of toxoplasmosis is only established by histopathologic demonstration of tachyzoites from obtained 
tissue biopsy. However, this invasive technique should be reserved for selected cases commonly outside the 
pregnancy [21]. 
4. Risk factors  
Humans acquired T. gondii by three principal routes as follows: food-borne; animal-to-human and mother-to-
child. Rare instances of transmission include organ transplant, blood transfusion, and laboratory workers. The 
risk of transmission to pregnant women does not differ from that of the general population.In general, for 
women, the risk of contracting the infection increases with increasing maternal age. In a study, the risk of 
developing T. gondii infection was found to increase by 7% for each year increase in maternal age [22]. Eating 
habits, especially consumption of raw or undercooked mean unwashed vegetables were reported as independent 
risk factors for toxoplasmosis[23]. The aforementioned risk factors are the main cited risk that lead to maternal 
seroconversion during pregnancy .Other important risk factors include living in rural areas (21)lower social 
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status and a low number of sheep owned and lower educational level were reported an association with high 
seroprevalence rates[24].  Unpasteurized goat's milk, having 3 or more cats and eating mussels were found to 
increase the risk of T. gondii infection (25). 
5. Treatment in pregnancy  
A Cochrane Review concluded that, prenatal treatment of established T. gondii does not prevent fetal infection, 
but it might reduce the severity of congenital toxoplasmosis[26]. The primary goal of treatment depends on 
presence or absent of fetal infectivity. Therefore, it important to performed polymerase chain reaction (PCR) on 
amniotic fluid to determine fetal status.  
The treatment of established fetal and maternal infection varies greatly according to the center policy. In 
general, spiramycin is recommended by many centers for the treatment of acute maternal infection with T. 
gondii  and the fetus is not infected. Spiramycin does not cross the placenta; therefore it has no benefit to the 
fetus if the amniotic fluid PCR analysis result is positive for T gondii. It is primarily used to prevent vertical 
transmission for the whole duration of pregnancy [27]. 
Pyrimethamine/sulfadiazine and leucovorin combination are used when fetal infection with T. Gondii is 
confirmed at or after 18 weeks of gestation, and it should be avoided in the first trimester, due to its 
teratogenicity and bone marrow toxicity in both mother and fetus [27]. Other workers suggest that 
pyrimethamine and sulfadiazine can use alternating with courses of spiramycin [28]. There is sufficiently 
evident that prenatal and postnatal treatment reduces the risk and severity of long-term symptoms. However, 
regular clinical and ophthalmologic examinations should be performed for many years following 
discontinuation of treatment [20, 29]. 
The recommended dose for treatment of T. gondii infection in pregnancy according to European Guidelines as 
follows; if fetal infection occurred in the first and early second trimesters (≤18 weeks of gestation) evident by 
positive PCR on amniotic fluid.   The key drug is spiramycin 1 g (3 million U) every 8 h until delivery. 
Confirmed fetal infection in late second and third trimesters (≥ 18 weeks of gestation) the recommended 
regimen includes a combination of pyrimethamine, sulfadiazine, Leucovorin. The recommended dose for 
pyrimethamine is 100 mg per day in two divided doses for two days as a loading dose, then 50 mg per day until 
delivery. Sulfadiazine is given in a dose of 75 mg/kg / day in two divided doses (maximum 4 g per day) for two 
days, then 100 mg/kg per day in two divided doses (maximum 4 g per day). Leucovorin( folinic acid) is given 
10-20 mg daily during and for one wk after pyrimethamine therapy to prevent bone marrow toxicity induced by 
pyrimethamine  [30].  
6. Prevention  
The definitive host for the parasite is members of family Felidae. Human gets infected through ingestion of 
contaminated water or food by oocysts that are passed in the feces of cats, and then the tachyzoites multiply in 
an intracellular location of the host. There is good evidence to prevent maternal in infection during pregnancy 
with subsequent reduction in fetal morbidity and mortality. According to the Centers for Disease Control and 
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Prevention, there are 15% of women within the reproductive age are immune to toxoplasmosis and the number 
of women gets infected during pregnancy is too small [6]. Many measures can help in reducing the risk from 
contracting toxoplasmosis infection during pregnancy, including well-cooked meat, pasteurized milk, and 
wearing gloves and washing hands while dealing domestic animals.  
7. Conclusion   
The diagnosis of T. gondii in pregnancy poses challenges to health caregivers. The primary aim of treatment in 
acute cases is to prevent vertical transmission to the fetus. However, reduction of seroconversion rate in 
pregnancy can be achieved by introduction of health education materials on potential risk factors and early 
antenatal visits. Assessment of prepregnancy and pregnancy titer for toxoplasmosis is important in determining 
fetal risk and provides the basis for parents counseling. Postnatal follow-up is essential as most of the babies are 
born apparently healthy. 
8. Recommendations 
Each hospital should develop its own and approach to screening for and treatment of toxoplasmosis in 
pregnancy. Serologic testing should be offered to all pregnant women whereas advanced testing should be 
performed for women considered to be at risk for primary Toxoplasma gondii infection. 
9. Limitations  
The review lack meta-analysis on risk factors of toxoplasmsosi during pregnancy during pregnancy. 
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